Trial team
Who is organising the trial?
The NHS-Galleri trial is organised and funded by a number of partner organisations.
The trial is run by The Cancer Research UK Cancer Prevention Trials Unit at QMUL, a team of cancer researchers and trial managers at Queen Mary University of London (QMUL). They coordinate this trial and will analyse the results. The unit was based at King’s College London before moving to QMUL.
The study is in partnership with the National Health Service (NHS) England. They provide follow-up and care related to the trial. The National Disease Registration Service provides data for the trial.
GRAIL, Inc. is a company in the United States (US) that developed the Galleri® test. They have also set up a branch in the UK, GRAIL Bio UK Ltd. (GRAIL), which is the main funder and organiser of this trial.
Who are the researchers leading the trial?
The Chief Investigators for the trial are Professor Richard Neal, a GP researcher at University of Exeter, and Professor Charles Swanton, a cancer researcher at University College London and the Francis Crick Institute. The Co-Investigator and Lead Statistician for the trial is Professor Peter Sasieni, a cancer researcher and statistician at Queen Mary University of London.
Professor Richard Neal FRCGP MBChB PhD is a part time GP and Professor of Primary Care. His research examines the interface between primary care/general practice and cancer, with a particular focus in cancer diagnostics.
Professor Charles Swanton FRCP BSc PhD is a clinician scientist. His research focuses on the management of metastatic cancer.
Professor Peter Sasieni CBE FMedSci PhD is Professor of Cancer Epidemiology and Director of the Cancer Research UK Cancer Prevention Trials Unit. His research focuses on cancer screening.
Who developed the Galleri test?
The Galleri test was developed by researchers at GRAIL, Inc. in the US. Results from trials using the Galleri test suggest that the test can work well.
Is anyone else involved?
GRAIL collaborates with patients and the public to make sure that information for participants in the NHS-Galleri trial is clear and understandable.
The trial uses the services of third-party organisations in the UK and outside the UK to help run the trial. They may handle information about people taking part in the trial. They will be required to do this safely and securely.